NasdaqCM:BULL
NasdaqCM:BULLCapital Markets

Webull (NasdaqCM:BULL) Surges 127% Over Last Quarter

Webull (NasdaqCM:BULL) recently experienced a remarkable surge in its share price, climbing 127% over the last quarter. A likely contributor to this impressive performance was the company's addition to the NASDAQ Composite Index on April 14, 2025, which significantly boosted its market profile. While the broader market remained steady over the past week and reported a 6% increase over the last year, Webull's inclusion in the index likely added significant weight to its exceptional rally,...
NYSE:MP
NYSE:MPMetals and Mining

MP Materials (NYSE:MP) Appoints David G. Infuso As Chief Accounting Officer

MP Materials (NYSE:MP) recently announced the appointment of David G. Infuso as Chief Accounting Officer, a move reflecting the company's focus on strengthening its financial leadership. While this leadership update is crucial, MP Materials' substantial 26% price increase over the last quarter aligns with broader market movement rather than singular company developments, as the overall market remained relatively flat. The company's production and financial performance, including record...
NasdaqGS:RXRX
NasdaqGS:RXRXBiotechs

Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal

Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a licensing agreement to integrate HealthVerity's extensive real-world data into its platforms. In the same week, Recursion reported significant advancements in its drug discovery initiatives and clinical studies, including dosing the first patient in a promising Phase 1 trial. Despite the broader market's flat performance over the past week, Recursion's stock price saw a 22% increase, suggesting that these developments reinforced...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Viking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735

Viking Therapeutics (NasdaqCM:VKTX) saw its stock rise by 11% over the last week, coinciding with significant developments in its clinical trials. The company's completion of subject enrollment for the Phase 2 clinical trial of VK2735, targeting weight loss, and promising results from earlier phases have bolstered investor confidence, contributing to the stock's positive movement. The recent announcements about both oral and subcutaneous formulations underscore the potential of VK2735. With...